312 related articles for article (PubMed ID: 20693850)
21. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
[TBL] [Abstract][Full Text] [Related]
22. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
23. Transient stimulation expands superior antitumor T cells for adoptive therapy.
Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
[TBL] [Abstract][Full Text] [Related]
24. Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.
Fang RH; Kroll AV; Zhang L
Small; 2015 Nov; 11(41):5483-96. PubMed ID: 26331993
[TBL] [Abstract][Full Text] [Related]
25. Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.
Oelke M; Schneck JP
Immunol Res; 2010 Jul; 47(1-3):248-56. PubMed ID: 20087680
[TBL] [Abstract][Full Text] [Related]
26. Adoptive Cellular Therapy (ACT) for Cancer Treatment.
Yang F; Jin H; Wang J; Sun Q; Yan C; Wei F; Ren X
Adv Exp Med Biol; 2016; 909():169-239. PubMed ID: 27240459
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of murine dendritic cell antitumor dysfunction in aging.
Grolleau-Julius A; Abernathy L; Harning E; Yung RL
Cancer Immunol Immunother; 2009 Dec; 58(12):1935-9. PubMed ID: 19082999
[TBL] [Abstract][Full Text] [Related]
28. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation.
Lu Y; Li L; Du J; Chen J; Xu X; Yang X; Ding C; Mao C
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55890-55901. PubMed ID: 34787393
[TBL] [Abstract][Full Text] [Related]
30. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
31. Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation.
Hickey JW; Vicente FP; Howard GP; Mao HQ; Schneck JP
Nano Lett; 2017 Nov; 17(11):7045-7054. PubMed ID: 28994285
[TBL] [Abstract][Full Text] [Related]
32. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.
Hamieh M; Chatillon JF; Dupel E; Bayeux F; Fauquembergue E; Maby P; Drouet A; Duval-Modeste AB; Adriouch S; Boyer O; Latouche JB
Front Immunol; 2021; 12():674276. PubMed ID: 34566953
[TBL] [Abstract][Full Text] [Related]
33. Adoptive T-cell therapy for malignant disorders.
Powell DJ; Levine BL
Haematologica; 2008 Oct; 93(10):1452-6. PubMed ID: 18827263
[No Abstract] [Full Text] [Related]
34. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
[TBL] [Abstract][Full Text] [Related]
35. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
[TBL] [Abstract][Full Text] [Related]
36. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.
Zappasodi R; Di Nicola M; Carlo-Stella C; Mortarini R; Molla A; Vegetti C; Albani S; Anichini A; Gianni AM
Haematologica; 2008 Oct; 93(10):1523-34. PubMed ID: 18728033
[TBL] [Abstract][Full Text] [Related]
37. Latex bead-based artificial antigen-presenting cells induce tumor-specific CTL responses in the native T-cell repertoires and inhibit tumor growth.
Shen C; Cheng K; Miao S; Wang W; He Y; Meng F; Zhang J
Immunol Lett; 2013 Feb; 150(1-2):1-11. PubMed ID: 23328744
[TBL] [Abstract][Full Text] [Related]
38. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
de Charette M; Marabelle A; Houot R
Eur J Cancer; 2016 Nov; 68():134-147. PubMed ID: 27755997
[TBL] [Abstract][Full Text] [Related]
39. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells.
Webb TJ; Bieler JG; Schneck JP; Oelke M
J Immunol Methods; 2009 Jul; 346(1-2):38-44. PubMed ID: 19446558
[TBL] [Abstract][Full Text] [Related]
40. Artificial antigen-presenting cells: artificial solutions for real diseases.
Oelke M; Krueger C; Giuntoli RL; Schneck JP
Trends Mol Med; 2005 Sep; 11(9):412-20. PubMed ID: 16103011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
